Integrative analysis of multi-omics datasets is revolutionizing cancer research and patient care. To take advantage of the full breadth of CRDC’s petabyte-scale data, EarlyDx will seamlessly integrate its liquid biopsy cloud-computing platform, a cfDNA–based bioinformatics platform with proprietary machine learning algorithms, with the CRDC data repositories and computational capacity in a cloud infrastructure. Liquid biopsies provide a non-invasive approach for interrogating the genomic and epigenomic profiles of tumors and can easily acquire a large number of specimens. Co-analysis of CRDC tissue-based TCGA, TARGET, CPTAC datasets with user-provided data from a tube of blood will ensure broad user adoption of CRDC. Our long-term goals are to advance our understanding of tumorigenesis, therapeutic resistance and response, and to improve patient care. Specifically, we will conduct the following aims: 1) establish a multidisciplinary team; 2) design, develop, and implement strategies for integration of EarlyDx liquid biopsy bioinformatics platform with CRDC; 3) recruit at least 25 users of an early phase prototype for usability testing; 4) report Phase I results to NCI, and plan for further development and commercialization. Our platform with CRDC integration will accelerate cancer research, and promote clinical applications such as cancer detection and treatment in broad populations.